CENTRAL FAX CENTER



Ernest Orlando Lawrence Berkeley National Laboratory Office of the Laboratory Counsel Patent Department MS 90B-0104



DATE:	12/17/04		•
TO:	Examiner Misook Yu	FAX:	(703) 872-9306
LOCATIO	N: In the United States Patent and Trademark Office	TEL:	(571) 272-0839
FROM:	Michelle S. Chew	FAX:	(510) 486-7896
LOCATIO	N: Building 90B	TEL:	(510) 495-2456

This facsimile contains confidential information which may also be privileged. Unless you are the addressee (or authorized to receive for the addressee) you may not copy, use or distribute it. If you have received it in error, please inform the LBNL Patent Department immediately by telephone or facsimile and return it promptly by mail to Patent Department, Lawrence Berkeley National Laboratory, One Cyclotron Road, MS 908-0104, Berkeley, Ca 94720.

PLEASE DELIVER TO EXAMINER MISOOK YU.

Practitioner's Docket No. IB-1398

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mina J. Bissell et al.

Application No.: 09/652,493

Group No.: 1642

Filed: August 31, 2000

Examiner: Yu

For: Design of Novel Drug Screens based on the Newly Found Role of Dystroglycan Proteolysis

in Tumor Cell Growth

REMARKS:

Dear Examiner Yu:

Attached to this cover sheet is a response to the Notice of Non-Compliant Amendment mailed 12/10/04 for the application listed above. If you encounter any problems with this transmission, please call me at (510) 495-2456. Thank you.

Respectfully submitted,

Michelle S. Chew, Esq.

Reg. No. 50,456

Ernest Orlando Lawrence Berkeley National Laboratory

One Cyclotron Road

1 Berkeley, California 94720

PAGE 02/08

DEC 1 7 2004

PTO/SB/21 (09-04) Approved for use through 07/31/2008, OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 09/652,493 Filing Date TRANSMITTAL August 31, 2000 First Named Inventor Mina J. Bissell FORM Art Unit 1642 Examiner Name Misook Yu (to be used for all correspondence after initial filing) Attorney Docket Number IB-1398 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittel Form Drawing(s) Appeal Communication to Board Licansing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC $|\mathbf{x}|$ (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please identify Terminal Disclaimer below): Extension of Time Request Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Lawrence Berkeley National Laboratory Signature Printed name Michelle S. Chew Reg. No. Date 50,456 2-17-2004 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature the

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

12/17/2004

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Sharon Kay Reineman

Typed or printed name

RECEIVED CENTRAL FAX CENTER

DEC 1 7 2004

Appl. No. 09/652,493 Amdt. Dated December 17, 2004 Reply to Office action of May 18, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

: 09/652,493

Applicant

: Mina J. Bissell et al.

Filed

August 31, 2000

Title

DESIGN OF NOVEL DRUG SCREENS BASED ON THE NEWLY

FOUND ROLE OF DYSTROGLYCAN PROTEOLYSIS IN TUMOR

CELL GROWTH

TC/A.U.

: 1642

Examiner

: Misook Yu

DocketNo. :

IB-1398

Honorable Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF FACSIMILE UNDER 37 C.F.R. § 1.8(a)(1)(i)(B)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being facsimile transmitted to the United States Patent and Trademark Office, at (703) 872-9306 on December 17, 2004.

121/31/04

Michelle S: Chew <u>Shaoon Kan Keinema</u>

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT MAILED 12/10/04

Dear Sir:

The following communication is responsive to the Notice of Non-Compliant Amendment mailed December 10, 2004. Accordingly, a Response is due on January 10, 2005 without extension. Thus, this Response is timely filed within the one month period of reply. Applicants request reconsideration of the above application in view of the following resubmitted claims. Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.